Supplementary tables: One-year budget impact of InTandem™: a novel neurorehabilitation system for individuals with chronic stroke walking impairment

These are peer-reviewed supplementary materials for the article 'One-year budget impact of InTandem™: a novel neurorehabilitation system for individuals with chronic stroke walking impairment' published in the Journal of Comparative Effectiveness Research.Supplemental Table 1: Sensitivity Analysis InputsSupplemental Table 2: Sensitivity Analysis: Inclusion of Recurrent Stroke-Related Hospitalization and LTC CostsReferencesAim: Chronic stroke walking impairment is associated with high healthcare resource utilization (HCRU) costs. InTandem™ is a neurorehabilitation system that autonomously delivers a rhythmic auditory stimulation (RAS)-based intervention for the at-home rehabilitation of walking impairment in adults in the chronic phase of stroke recovery. This study was conducted to estimate the budget impact of InTandem in comparison with currently available intervention strategies for improvement of gait/ambulation in individuals with chronic stroke walking impairment. Methods & materials: A budget impact analysis (BIA) for InTandem was conducted based on a 1-million-member US third-party payer perspective over a 1-year time horizon. Key inputs for the budget impact model were: costs for each intervention strategy (InTandem, physical therapy, self-directed walking and no treatment), HCRU costs for persons with chronic stroke and anticipated HCRU cost offsets due to improvements in gait/ambulatory status as measured by self-selected comfortable walking speed (based on functional ability). In addition to the reference case analysis, a sensitivity analysis was conducted. Results: Based on the reference case, introduction of InTandem was projected to result in overall cost savings of $439,954 in one year. Reduction of HCRU costs (-$2,411,778) resulting from improved walking speeds with InTandem offset an increase in intervention costs (+$1,971,824). Demonstrations of cost savings associated with InTandem were robust and were consistently evident in nearly all scenarios evaluated in the sensitivity analysis (e.g., with increased/decreased patient shares, increased HCRU cost or increased InTandem rental duration). Conclusion: The InTandem system is demonstrated to improve walking and ambulation in adults in the chronic phase of stroke recovery after a five-week intervention period. The BIA predicts that introduction of InTandem will be associated with overall cost savings to the payer.

本数据集为发表在《比较疗效研究杂志》上的文章《InTandem™系统一年预算影响：一种针对慢性卒中步态障碍患者的创新神经康复系统》的同行评审补充材料。补充表1：敏感性分析输入；补充表2：敏感性分析：纳入复发性卒中相关住院和长期护理成本；参考文献；研究目标：慢性卒中步态障碍与高医疗资源利用（HCRU）成本相关。InTandem™是一种神经康复系统，可自主提供基于节律听觉刺激（RAS）的干预措施，用于慢性卒中康复期成人步态障碍的居家康复。本研究旨在估算与目前可用的改善慢性卒中步态障碍患者步态/行走能力的干预策略相比，InTandem系统的预算影响。方法与材料：基于100万美国第三方支付者的视角，在一年时间范围内进行了InTandem系统的预算影响分析（BIA）。预算影响模型的关键输入包括：每种干预策略（InTandem、物理治疗、自我引导行走和无治疗）的成本，慢性卒中患者的HCRU成本以及因步态/行走状况改善（基于自我选择的舒适行走速度，根据功能能力）而预期的HCRU成本抵消。除了参考案例分析外，还进行了敏感性分析。结果：基于参考案例，引入InTandem预计将在一年内实现总体成本节省439,954美元。InTandem提高行走速度导致的HCRU成本降低（-2,411,778美元）抵消了干预成本增加（+1,971,824美元）。与InTandem相关的成本节省证据稳健，并在敏感性分析中评估的几乎所有场景中均持续显现（例如，随着患者份额的增加/减少、HCRU成本的增加或InTandem租赁期限的增加）。结论：InTandem系统在五周干预期后显示出改善慢性卒中康复期成人步态和行走的潜力。预算影响分析预测，引入InTandem将与支付者的总体成本节省相关。